Management of traditional risk factors for the development and progression of chronic kidney disease

被引:18
作者
Lo, Robin [1 ]
Narasaki, Yoko [1 ,2 ]
Lei, Sean [1 ]
Rhee, Connie M. [1 ,2 ]
机构
[1] Univ Calif Irvine, Harold Simmons Ctr Chron Dis Res & Epidemiol, Div Nephrol & Hypertens, Orange, CA 92868 USA
[2] Tibor Rubin Vet Affairs Med Ctr, Long Beach, CA 90822 USA
基金
日本学术振兴会; 美国国家卫生研究院;
关键词
chronic kidney disease; risk factors; traditional; BLOOD-PRESSURE CONTROL; HORMONE REPLACEMENT THERAPY; TYPE-2 DIABETES FOCUS; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; RENAL-FUNCTION; HEART-FAILURE; MESOAMERICAN NEPHROPATHY; MASKED HYPERTENSION; PRIMARY PREVENTION;
D O I
10.1093/ckj/sfad101
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Lay Summary In this Review, we discuss major risk factors for incident chronic kidney disease (CKD) and CKD progression categorized across cardiovascular (i.e. hypertension, dyslipidaemia, cardiorenal syndrome), endocrine (i.e. diabetes mellitus, hypothyroidism, testosterone), lifestyle (i.e. obesity, dietary factors, smoking), and genetic/environmental (i.e. CKDu/Mesoamerican nephropathy, APOL1, herbal nephropathy) domains, as well as scope, mechanistic underpinnings, and management. Chronic kidney disease (CKD) and its downstream complications (i.e. cardiovascular) are a major source of morbidity worldwide. Additionally, deaths due to CKD or CKD-attributable cardiovascular disease account for a sizeable proportion of global mortality. However, the advent of new pharmacotherapies, diagnostic tools, and global initiatives are directing greater attention to kidney health in the public health agenda, including the implementation of effective strategies that (i) prevent kidney disease, (ii) provide early CKD detection, and (iii) ameliorate CKD progression and its related complications. In this Review, we discuss major risk factors for incident CKD and CKD progression categorized across cardiovascular (i.e. hypertension, dyslipidemia, cardiorenal syndrome), endocrine (i.e. diabetes mellitus, hypothyroidism, testosterone), lifestyle (i.e. obesity, dietary factors, smoking), and genetic/environmental (i.e. CKDu/Mesoamerican nephropathy, APOL1, herbal nephropathy) domains, as well as scope, mechanistic underpinnings, and management.
引用
收藏
页码:1737 / 1750
页数:14
相关论文
共 144 条
[41]   Lipid Accumulation and Chronic Kidney Disease [J].
Gai, Zhibo ;
Wang, Tianqi ;
Visentin, Michele ;
Kullak-Ublick, Gerd A. ;
Fu, Xianjun ;
Wang, Zhenguo .
NUTRIENTS, 2019, 11 (04)
[42]   Uddanam Nephropathy/Regional Nephropathy in India: Preliminary Findings and a Plea for Further Research [J].
Ganguli, Anirban .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (03) :344-348
[43]   Heat stress, dehydration, and kidney function in sugarcane cutters in EI Salvador - A cross-shift study of workers at risk of Mesoamerican nephropathy [J].
Garcia-Trabanino, Ramon ;
Jarquin, Emmanuel ;
Wesseling, Catharina ;
Johnson, Richard J. ;
Gonzalez-Quiroz, Marvin ;
Weiss, Ilana ;
Glaser, Jason ;
Jose Vindell, Juan ;
Stockfelt, Leo ;
Roncal, Carlos ;
Harra, Tamara ;
Barregard, Lars .
ENVIRONMENTAL RESEARCH, 2015, 142 :746-755
[44]   Association between body mass index and CKD in apparently healthy men [J].
Gelber, RP ;
Kurth, T ;
Kausz, AT ;
Manson, JAE ;
Buring, JE ;
Levey, AS ;
Gaziano, JM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (05) :871-880
[45]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
[46]   Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J].
Gerstein, Hertzel C. ;
Colhoun, Helen M. ;
Dagenais, Gilles R. ;
Diaz, Rafael ;
Lakshmanan, Mark ;
Pais, Prem ;
Probstfield, Jeffrey ;
Riesmeyer, Jeffrey S. ;
Riddle, Matthew C. ;
Ryden, Lars ;
Xavier, Denis ;
Atisso, Charles Messan ;
Dyal, Leanne ;
Hall, Stephanie ;
Rao-Melacini, Purnima ;
Wong, Gloria ;
Avezum, Alvaro ;
Basile, Jan ;
Chung, Namsik ;
Conget, Ignacio ;
Cushman, William C. ;
Franek, Edward ;
Hancu, Nicolae ;
Hanefeld, Markolf ;
Holt, Shaun ;
Jansky, Petr ;
Keltai, Matyas ;
Lanas, Fernando ;
Leiter, Lawrence A. ;
Lopez-Jaramillo, Patricio ;
Cardona Munoz, Ernesto German ;
Pirags, Valdis ;
Pogosova, Nana ;
Raubenheimer, Peter J. ;
Shaw, Jonathan E. ;
Sheu, Wayne H-H ;
Temelkova-Kurktschiev, Theodora .
LANCET, 2019, 394 (10193) :121-130
[47]  
He J, 2015, J ENG-JOE, P1, DOI [10.1681/ASN.2015010022, 10.1049/joe.2015.0102]
[48]   Dapagliflozin in Patients with Chronic Kidney Disease [J].
Heerspink, Hiddo J. L. ;
Stefansson, Bergur V. ;
Correa-Rotter, Ricardo ;
Chertow, Glenn M. ;
Greene, Tom ;
Hou, Fan-Fan ;
Mann, Johannes F. E. ;
McMurray, John J. V. ;
Lindberg, Magnus ;
Rossing, Peter ;
Sjostrom, C. David ;
Toto, Roberto D. ;
Langkilde, Anna-Maria ;
Wheeler, David C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1436-1446
[49]   Renal Denervation in Moderate to Severe CKD [J].
Hering, Dagmara ;
Mahfoud, Felix ;
Walton, Antony S. ;
Krum, Henry ;
Lambert, Gavin W. ;
Lambert, Elisabeth A. ;
Sobotka, Paul A. ;
Boehm, Michael ;
Cremers, Bodo ;
Esler, Murray D. ;
Schlaich, Markus P. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (07) :1250-1257
[50]   Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials [J].
Herrington, William G. ;
Emberson, Jonathan ;
Mihaylova, Borislava ;
Blackwell, Lisa ;
Reith, Christina ;
Solbu, Marit D. ;
Mark, Patrick B. ;
Fellstrom, Bengt ;
Jardine, Alan G. ;
Wanner, Christoph ;
Holdaas, Hallvard ;
Fulcher, Jordan ;
Haynes, Richard ;
Landray, Martin J. ;
Keech, Anthony ;
Simes, John ;
Collins, Rory ;
Baigent, Colin .
LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (10) :829-839